nor-Binaltorphimine Dihydrochloride: Selective κ-Opioid Receptor Antagonist for Circuit and Pain Research

Executive Summary: nor-Binaltorphimine dihydrochloride is a potent, selective κ-opioid receptor antagonist used to dissect opioid receptor function in pain modulation and neural circuitry (APExBIO). It exhibits a molecular weight of 734.72 g/mol and a chemical formula of C40H43N3O6·2HCl, with solubility below 18.37 mg/mL in DMSO. Its action as a κ-opioid receptor antagonist has enabled key discoveries in the control of mechanical allodynia and the mapping of descending inhibitory pain pathways (Huo et al. 2023). The compound must be stored at -20°C to maintain stability, with prompt use of prepared solutions recommended. APExBIO supplies nor-Binaltorphimine dihydrochloride (B6269) with ≥98% purity, strictly for research use.

Biological Rationale

κ-Opioid receptors (KORs) are G protein-coupled receptors involved in pain, stress, and addiction pathways (related article). Nor-Binaltorphimine dihydrochloride is used to study these receptors by selectively blocking their activity, allowing researchers to parse the contribution of KOR-mediated signaling from other opioid pathways (APExBIO). This selectivity is critical in mapping neural circuits controlling pain duration and laterality, such as the brain-to-spinal Oprm1–Pdyn–SDH axis elucidated in recent allodynia research (Huo et al. 2023). Dysfunction in KOR signaling has been implicated in chronic pain, addiction, and affective disorders, justifying the need for selective antagonists in mechanistic and translational studies (see also).

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride binds selectively to κ-opioid receptors, inhibiting their function without significant activity at μ- or δ-opioid receptors (Huo et al. 2023). It achieves high affinity through its bivalent molecular structure, designed for KOR selectivity. Upon administration, the compound competes with endogenous ligands such as dynorphin, preventing KOR-mediated G protein signaling and reducing inhibition of neuronal excitability (related piece). Blockade of KORs in the spinal dorsal horn (SDH) has been shown to prolong bilateral mechanical allodynia, confirming its critical role in inhibitory pain pathways (Huo et al. 2023).

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride selectively inhibits κ-opioid receptor-mediated signal transduction, with negligible effect on μ- or δ-opioid receptors (Huo et al. 2023, DOI).
• In vivo, blockade of spinal KORs with nor-Binaltorphimine induces persistent, bilateral mechanical allodynia following nerve injury or capsaicin administration (Huo et al. 2023, DOI).
• Experimental application in rodents confirms that nor-Binaltorphimine dihydrochloride unmasks underlying excitatory pain circuits by disabling KOR-mediated inhibition in the SDH (DOI).
• Benchmarked purity for APExBIO's B6269 product is ≥98% (manufacturer's certificate, APExBIO).
• The compound's maximal solubility in DMSO is 18.37 mg/mL at room temperature (manufacturer's data, APExBIO).
• Long-term storage at -20°C preserves compound stability; solutions are unstable and require immediate use (manufacturer recommendations, APExBIO).

Applications, Limits & Misconceptions

nor-Binaltorphimine dihydrochloride is applied in opioid receptor pharmacology, pain modulation research, and the study of addiction and dependence mechanisms. It is used in opioid receptor antagonist assays and to elucidate opioid receptor-mediated signal transduction pathways. Its selectivity enables clear attribution of observed biological effects to KOR signaling (see mechanistic analysis). This extends prior reviews by offering practical assay parameters and new circuit insights from recent allodynia models. For example, blocking spinal KORs with nor-Binaltorphimine reveals the role of the hypothalamic dynorphin/spinal KOR inhibitory system in modulating pain laterality and duration (Huo et al. 2023). In contrast to previous articles that focus on general receptor pharmacology, the present piece details use-cases in neural circuit dissection and translational pain models.

Common Pitfalls or Misconceptions

• nor-Binaltorphimine dihydrochloride does not block μ- or δ-opioid receptors at standard experimental concentrations; off-target effects are minimal but possible at high doses.
• It does not reverse established opioid dependence or treat clinical pain; it is strictly for research use only.
• Solutions of nor-Binaltorphimine dihydrochloride are unstable at room temperature and must be used promptly after preparation.
• The compound's in vivo effects require controlled administration; systemic dosing may produce different results than localized spinal application.
• It should not be used for diagnostic or therapeutic purposes in humans or animals.

Workflow Integration & Parameters

nor-Binaltorphimine dihydrochloride (B6269) is best dissolved in DMSO at concentrations up to 18.37 mg/mL at ambient temperature (APExBIO). For in vivo rodent studies, typical dosing ranges from 1–10 mg/kg via intrathecal or systemic routes. For in vitro opioid receptor antagonist assays, working concentrations are often 10–1000 nM, depending on cell type and assay sensitivity. Prepare solutions fresh prior to use, as stability is limited; avoid repeated freeze-thaw cycles. Shipments require blue ice to maintain integrity. Store powder at -20°C under desiccated conditions. For further workflow guidance and comparison, see the Precision in Opioid Circuit Studies article, which emphasizes cross-model reproducibility; the present article details new benchmarks from recent circuit mapping studies.

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride remains the gold standard selective κ-opioid receptor antagonist for dissecting opioid receptor-mediated signaling in pain and circuit research. Its high specificity, validated by recent neural circuit mapping studies, enables mechanistic clarity in both basic and translational models (Huo et al. 2023). With careful handling and integration into receptor antagonist workflows, it supports the development of next-generation analgesic and addiction interventions. For detailed product specifications and ordering, visit the APExBIO B6269 product page.